Albert Bourla, Chairman and CEO of Pfizer (PFE), has demonstrated a clear pattern of insider activity focused exclusively on his company’s stock, with no recent trades in other securities. Over the course of 43 reported transactions, Bourla has accumulated a net buying bias, with total purchases valued at $48.1 million outweighing sales of $36.4 million. His most significant transactions include a $16.6 million sale on February 25, 2026, and a $12.6 million sale the same day, alongside smaller, routine transactions—often in the hundreds of dollars—likely tied to automatic share dispositions or tax-related events. Notably, his recent filings show no new buys or sells since March 2026, when he executed a minor $43,325 transaction. The bulk of his high-value sales occurred in early 2026, while earlier activity in 2025 included a $14.2 million sale in late February of that year. Bourla’s trading history suggests a disciplined approach, with large, periodic sales offset by steady, smaller acquisitions, though the absence of recent activity leaves his current positioning unclear. All transactions remain confined to Pfizer, reinforcing his alignment with the company’s performance.
AI-assisted summary